Last updated: September 6, 2026
Trientine tetrahydrochloride is a specialty orphan drug used for maintenance treatment of Wilson disease. In the United States, it is marketed as Cuvrior by Orphalan. The product received FDA approval in May 2022 and has seven years of orphan-drug exclusivity, subject to statutory exceptions, through May 2029. Its commercial opportunity is constrained by a small diagnosed patient population, but pricing, chronic treatment duration, limited alternatives, and high switching barriers support substantial revenue per treated patient.
The principal commercial risks are diagnosis rates, payer management, competition from other trientine products, generic or 505(b)(2) entry after exclusivity, and the absence of broad label expansion. Publicly disclosed audited sales data for Cuvrior are limited because Orphalan is privately held.
What is trientine tetrahydrochloride used for?
Trientine tetrahydrochloride is an oral copper-chelating agent for Wilson disease, a rare inherited disorder involving impaired copper transport and copper accumulation in the liver, brain, and other tissues.
Cuvrior is indicated for adults with stable Wilson disease who are clinically stable on penicillamine and are being switched to trientine tetrahydrochloride. The FDA-approved product is supplied as 300 mg tablets. The label requires administration on an empty stomach and separates dosing from food and certain mineral supplements because absorption can be affected.[1]
The product is not positioned as a broad first-line therapy for all Wilson disease patients. Its US label is narrower than the overall clinical use of trientine, which limits the immediately addressable market but supports a defined switching population.
How does trientine tetrahydrochloride work?
Trientine binds copper and promotes urinary excretion. It is used when penicillamine is poorly tolerated, contraindicated, or clinically unsuitable. The major clinical value proposition is reduced reliance on penicillamine, which has a substantial adverse-event burden and requires laboratory monitoring.
What is the FDA status of Cuvrior?
The FDA approved Cuvrior on May 26, 2022, under the 505(b)(2) pathway.[2] The approval relied in part on pharmacokinetic data and clinical evidence supporting the switch from penicillamine in stable adult patients.
| Regulatory item |
Status |
| Active ingredient |
Trientine tetrahydrochloride |
| Brand |
Cuvrior |
| Sponsor |
Orphalan |
| FDA application |
NDA 214115 |
| Dosage form |
300 mg oral tablet |
| Indication |
Stable adult Wilson disease patients switching from penicillamine |
| FDA approval |
May 26, 2022 |
| Orphan-drug exclusivity |
Expected to extend through May 2029 |
| FDA pathway |
505(b)(2) |
| Biosimilar pathway |
Not applicable |
The product is also marketed in Europe as Cuprior. The European Medicines Agency authorized Cuprior in 2017 for Wilson disease in patients who are intolerant of D-penicillamine and for patients who cannot continue that treatment.[3]
When does trientine tetrahydrochloride lose exclusivity?
The key US regulatory exclusivity date is May 2029, when Cuvrior’s seven-year orphan-drug exclusivity is scheduled to expire. Orphan exclusivity prevents FDA approval of the same drug for the same indication during the exclusivity period unless the sponsor cannot assure sufficient quantity or the competing product is shown to be clinically superior.
Orphan exclusivity is separate from patent protection. A product may retain enforceable patents after orphan exclusivity ends, and a competitor may challenge patents before their nominal expiration.
What patents protect Cuvrior?
Cuvrior’s protection is likely to include composition, formulation, dosage, manufacturing, and use claims. The commercially important distinction is between:
- Patents covering trientine tetrahydrochloride itself.
- Patents covering the tablet formulation and stability profile.
- Patents covering administration or patient-switching methods.
- Patents covering manufacturing or purification processes.
Public patent databases identify multiple patent families associated with trientine formulations and Orphalan-related development. The strength of those patents depends on claim scope, written-description support, prosecution history, terminal disclaimers, and whether a generic applicant can design around the protected formulation.
The relevant patent term for US patents generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory provisions.[4] Exact Orange Book-listed patent coverage should be distinguished from broader patent-family coverage because not every formulation or process patent is necessarily listed for an approved drug.
What is the Orange Book status of Cuvrior?
Cuvrior is an FDA-approved small-molecule drug and is eligible for Orange Book listing. Orange Book-listed patents can support a Paragraph IV certification and patent litigation under the Hatch-Waxman Act.
The commercial significance of Orange Book protection is timing. If a generic applicant files an abbreviated new drug application with a Paragraph IV certification, the patent holder may file suit within 45 days and obtain an automatic 30-month stay of approval, subject to statutory exceptions and court decisions.[5]
How large is the trientine tetrahydrochloride market?
The market is a small, high-value orphan market rather than a volume-driven pharmaceutical category.
Wilson disease prevalence estimates commonly range from approximately one patient per 30,000 to one per 100,000 people, with substantial underdiagnosis and delayed diagnosis.[3,6] In the United States, the treated population is likely in the low tens of thousands or below, depending on the definition used. Only a portion of these patients are eligible for the Cuvrior label because the FDA indication focuses on stable adults switching from penicillamine.
The addressable population has four layers:
| Market layer |
Commercial relevance |
| All people with Wilson disease |
Epidemiologic ceiling |
| Diagnosed patients |
Limited by diagnostic delay and specialist access |
| Treated patients |
Reduced by adherence, transplantation, and mortality |
| Stable adults on penicillamine |
Core US Cuvrior label population |
Treatment is chronic, often lifelong. This creates recurring revenue and reduces dependence on one-time prescriptions. Patients who respond to therapy are unlikely to switch repeatedly because copper control requires ongoing monitoring and treatment continuity.
What drives the financial trajectory of Cuvrior?
Cuvrior’s revenue trajectory is driven more by price and penetration than by rapid patient-volume growth.
Pricing and net revenue
Orphan drugs for Wilson disease can command high annual gross prices because of the small population, chronic use, specialist prescribing, and lack of interchangeable products. Actual net revenue depends on rebates, specialty-pharmacy concessions, patient assistance, government program discounts, and payer restrictions.
Public sources do not provide a reliable, audited Cuvrior revenue series. Orphalan is privately held, and product-level US sales are not reported in the same manner as sales from large publicly traded pharmaceutical companies.
A practical commercial model is:
Annual revenue = treated patients × annual net price × adherence and persistence
The model is sensitive to three variables:
- Net price per patient.
- Conversion of stable penicillamine patients.
- Persistence on Cuvrior.
Patient growth alone is unlikely to produce a large market. A high price per patient, broader physician adoption, and successful conversion from penicillamine are more important.
Patient conversion
The largest near-term opportunity is conversion of patients who are stable on penicillamine. Cuvrior’s US label creates a defined switching population, but it also limits initial use in patients who are newly diagnosed, unstable, or already receiving another trientine product.
Conversion may be slowed by:
- Physician comfort with existing chelation therapy.
- Payer prior authorization.
- Clinical concerns about switching stable patients.
- Product availability and specialty-pharmacy logistics.
- Patient adherence to fasting administration requirements.
How does Cuvrior compare with competing Wilson disease drugs?
| Product |
Active ingredient |
Principal role |
Commercial position |
| Cuvrior |
Trientine tetrahydrochloride |
Stable adults switching from penicillamine |
Newer US orphan product |
| Cuprior |
Trientine tetrahydrochloride |
European Wilson disease treatment |
European reference product |
| Syprine |
Trientine hydrochloride |
Wilson disease treatment |
Established US competitor |
| Depen |
Penicillamine |
Chelation therapy |
Older, lower-cost alternative |
| Galzin |
Zinc acetate |
Maintenance therapy |
Non-chelation alternative |
Syprine is particularly important because it contains trientine hydrochloride rather than trientine tetrahydrochloride. Salt form, tablet composition, labeling, dose expression, and formulation are commercially relevant. A competitor may not need to duplicate every feature of Cuvrior if it can obtain approval through an applicable regulatory pathway using a different formulation or reference product.
Cuvrior’s potential advantages include a newer formulation, a defined FDA-approved switching indication, and commercial support from an orphan-disease specialist. Its disadvantages include a small label, likely premium pricing, and competition from established trientine and penicillamine products.
Which companies are challenging trientine tetrahydrochloride exclusivity?
No major public Paragraph IV litigation campaign has established a clear near-term generic launch threat for Cuvrior based on publicly available regulatory and court records. The principal competitive risk is more likely to emerge as the May 2029 orphan-exclusivity expiration approaches.
Potential challengers could include:
- Generic manufacturers with experience in orphan drugs.
- Specialty pharmaceutical companies using 505(b)(2).
- Manufacturers of trientine hydrochloride seeking broader product positioning.
- Regional suppliers pursuing European or non-US approvals.
A generic applicant could challenge listed formulation or method-of-use patents through Paragraph IV certification. A successful challenge could accelerate entry. A non-infringing filing could avoid some patent claims while still facing regulatory, manufacturing, and commercial barriers.
What formulation and manufacturing barriers protect the product?
Formulation barriers may be commercially more important than the active ingredient. Trientine products must address stability, tablet integrity, dosing accuracy, packaging, and administration conditions. The drug’s use with food, antacids, iron, zinc, and other mineral products creates labeling and patient-management requirements.
Manufacturing risks include:
- Consistent control of the tetrahydrochloride salt.
- Impurity management.
- Stability through shelf life.
- Reproducible dissolution and bioavailability.
- Specialized packaging and supply continuity.
These barriers do not create permanent protection, but they can delay competition and raise the cost of a generic launch. Orphan markets also provide limited manufacturing scale, making supply reliability strategically important.
What generic launch risks exist after May 2029?
The most plausible US launch scenarios are:
| Scenario |
Timing |
Market effect |
| No timely challenge |
2029 or later |
Cuvrior retains high share |
| One approved competitor |
After exclusivity or patent resolution |
Moderate price and share pressure |
| Multiple generic entrants |
After patent barriers fall |
Greater price erosion |
| 505(b)(2) entrant |
Potentially before full patent expiry |
Targeted competition based on formulation or clinical positioning |
| Continued patent litigation |
Launch delayed |
Maintains branded pricing longer |
Generic erosion may be slower than in high-volume primary-care markets. The patient population is small, prescriber concentration is high, and payers may prefer continuity for patients who are clinically stable. However, orphan status does not prevent substantial price erosion once competitors establish an approved alternative.
What is the commercial outlook for trientine tetrahydrochloride?
The outlook is positive but limited in scale. Cuvrior has a defensible orphan-drug position, a chronic-use model, and a clinically recognizable switching opportunity. Revenue can grow through specialist adoption, diagnosis expansion, international commercialization, and conversion of penicillamine users.
The product is unlikely to become a mass-market drug. Its value is concentrated in recurring revenue per patient and the strategic value of an orphan-disease platform. The main inflection points are:
- US market penetration after the 2022 approval.
- Payer access and specialty-pharmacy execution.
- Label expansion into additional Wilson disease populations.
- European sales of Cuprior.
- Patent and regulatory activity before May 2029.
- The emergence of trientine generic or 505(b)(2) competitors.
Key Takeaways
- Trientine tetrahydrochloride is marketed in the US as Cuvrior and in Europe as Cuprior.
- Cuvrior received FDA approval on May 26, 2022, for stable adults with Wilson disease switching from penicillamine.
- US orphan-drug exclusivity is expected to run through May 2029.
- The market is small but supports recurring, high-value chronic treatment.
- Revenue depends on net price, conversion from penicillamine, diagnosis rates, and treatment persistence.
- Syprine, trientine hydrochloride, penicillamine, and zinc acetate are the primary competitive reference points.
- Product-specific public revenue disclosure is limited because Orphalan is privately held.
- Generic risk is likely to increase as the 2029 orphan-exclusivity date approaches.
- Formulation, stability, manufacturing, and regulatory barriers may delay competition but are unlikely to prevent it permanently.
FAQs
Is trientine tetrahydrochloride the same as trientine hydrochloride?
No. They are different salt forms of the same chelating active moiety. Cuvrior contains trientine tetrahydrochloride, while Syprine contains trientine hydrochloride.
Is Cuvrior a biologic or a generic drug?
Cuvrior is a chemically synthesized small-molecule drug. It is not a biologic and is not subject to the biosimilar pathway. A competing product would generally pursue an ANDA, 505(b)(2), or another applicable small-molecule pathway.
Does Cuvrior have pediatric FDA approval?
The core FDA indication is for adults with stable Wilson disease switching from penicillamine. Pediatric use may occur in clinical practice under specialist supervision, but the commercial label should be distinguished from broader clinical use.
Can a generic launch before May 2029?
A generic could seek approval before May 2029, but orphan-drug exclusivity, listed patents, patent litigation, and regulatory requirements can prevent commercial marketing during the protected period. The practical launch date depends on the specific product and legal pathway.
What is the largest commercial risk for Cuvrior?
The largest commercial risk is a combination of narrow labeling and future competition from trientine products that obtain approval through a different formulation, salt form, or regulatory pathway. Limited diagnosis and payer controls are the principal near-term growth constraints.
References
- U.S. Food and Drug Administration. (2022). Cuvrior (trientine tetrahydrochloride) tablets: Prescribing information.
- U.S. Food and Drug Administration. (2022). FDA approves treatment for Wilson disease.
- European Medicines Agency. (2017). Cuprior: EPAR product information.
- United States Patent and Trademark Office. (2024). General information concerning patents.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
- Trocello, J. M., Broussolle, E., Girardot-Tinica, C., Pelosse, M., Lachaux, A., & Lloyd, C. (2013). Wilson’s disease, 100 years later. Revue Neurologique, 169(12), 936-943.
